What are you looking for? Search Common searches: Intranet, Contact, Map, Professionals, Teaching units, Research groups, Fulltext search Tipus de contingut Professionals Projects Teaching Units Collaborating entities News Activities - Any - Search News Vall d’Hebron tests the efficacy of a drug to treat neuroblastoma, a highly aggressive form of paediatric tumour The study shows the therapeutic effect of a new drug called 4SC-205 in new mouse neuroblastoma models, where it is effective in reducing the growth of the tumour. News Vall d'Hebron identifies that patients with diabetes and myocardial insulin resistance have high cardiovascular risk Researchers have detected for the first time that people with type 2 diabetes who have insulin resistance in the myocardium have structural alterations of the heart and more calcifications in the coronary arteries that increase their risk of cardiovascular disease. News A program to support patients with primary immunodeficiencies at Vall d'Hebron expands to Bellvitge Hospital The project "I have PID. I'm an adult and I'm not alone" offers telematic sessions to improve the emotional well-being of adult patients with this type of disease. News Researchers identify a molecule that could be involved in the formation of bone metastases in prostate cancer A group of researchers from Vall d’Hebron Research, IDIBELL and UB has identified a molecule involved in bone metastasis associated with prostate cancer that could be useful in the design of new therapies for its treatment. News A phase I clinical trial with Vall d'Hebron participation shows good results of a drug against childhood cancer Dr. Lucas Moreno and Dr. Constantino Sábado, researchers of the Translational Research Group in Childhood and Adolescent Cancer, are two of the leaders of the international study. News A Vall d’Hebron study relates the impact of obesity to cognitive impairment The mechanisms in obesity that cause mild cognitive impairment are similar to those of type 2 diabetes. Fat is a powerful cerebral toxin and risk factor: it causes delayed reaction times in both executive function and attention. News Vall d’Hebron participates in RESPONSE, a global phase III clinical trial for the treatment of primary biliary cholangitis The innovative oral drug could provide a new therapeutic option for people with PBC who have not obtained the recommended therapeutic outcome or who do not tolerate first line therapy and cannot continue their treatment. News Recruitment of volunteers starts for the Phase III clinical trial of the HIPRA COVID-19 vaccine The trial, which already has AEMPS authorisation, will be conducted in Spain, Portugal and Italy. News Celebrem la II Jornada d’Actualització en Infeccions de Transmissió Sexual en el context de la infecció pel VIH L'objectiu de la jornada és revisar les Infeccions de Transmissió Sexual (ITS) amb major impacte clínic i de salut pública amb un enfocament teòric-pràctic a través de casos clínics interactius que facilitin la discussió i l’aprenentatge. News The story ‘We love you, little brave!’ donates its benefits to the Pediatric Cardiology Service of Vall d'Hebron Anna Gutiérrez's son was born in November 2019 with a congenital heart disease, for which he was operated on when he was five days old. Experience that inspired her to write the story ‘We love you, little brave!’. Pagination Previous page ‹‹ Page 109 Next page ››